<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2110246085
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Flamex
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CELECOXIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        37.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JORDAN SWEEDEN COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Flamex is used in adults for the relief of signs and symptoms of Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis.<br />Flamex belongs to a group of medicinal products called nonsteroidal anti-inflammatory drugs (NSAID), and specifically a sub-group known as (COX-2) inhibitors.<br />Your body makes prostaglandins that may cause pain and inflammation. In conditions such as rheumatoid arthritis and osteoarthritis your body makes more of these. Flamex acts by reducing the production of prostaglandins, thereby reducing the pain and inflammation.<br />You should expect your medicine to start working within hours of taking the first dose, but you may not experience a full effect for several days.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>A. Do not take Flamex:</strong><br />&bull; If you are allergic to Celecoxib or any of the other ingredients of this medicine (listed in section 6).<br />&bull; If you have had an allergic reaction to a group of medicines called &ldquo;sulphonamides&rdquo; (e.g. some antibiotics used to treat infections).<br />&bull; If you currently have an ulcer in your stomach or intestines, or bleeding in your stomach or intestines.<br />&bull; If as a result of taking acetylsalicylic acid or any other anti-inflammatory and pain-relieving medicine (NSAID) you have had asthma, nose polyps, severe nose congestion, or an allergic reaction such as an itchy skin rash, swelling of the face, lips, tongue or throat, breathing difficulties or wheezing.<br />&bull; If you are pregnant. If you can become pregnant during ongoing treatment you should discuss methods of contraception with your doctor.<br />&bull; If you are breast-feeding.<br />&bull; If you have severe liver disease.<br />&bull; If you have severe kidney disease.<br />&bull; If you have an inflammatory disease of the intestines such as ulcerative colitis or Crohn&rsquo;s disease.<br />&bull; If you have heart failure, established ischaemic heart disease, or cerebrovascular disease, e.g. you have been diagnosed with a heart attack, stroke, or transient ischaemic attack (temporary reduction of blood flow to the brain; also known as &ldquo;mini-stroke&rdquo;), angina, or blockages of blood vessels to the heart or brain.<br />&bull; If you have or have had problems with your blood circulation (peripheral arterial disease) or if you have had surgery on the arteries of your legs.<br />Do not take this medicine if any of the above apply to you.<br />If you are not sure, talk to your doctor or pharmacist before taking Flamex.</p><p><strong>B. Take special care with Flamex:</strong><br />Talk to your doctor or pharmacist before taking Flamex:<br />&bull; If you have previously had an ulcer or bleeding in your stomach or intestines. (Do not take Flamex if you currently have an ulcer or bleeding in your stomach or intestine).<br />&bull; If you are taking acetylsalicylic acid (even at low dose for heart protective purposes).<br />&bull; If you use medicines to reduce blood clotting (e.g. warfarin/warfarin like anticoagulants or novel oral anti-clotting medicines, e.g. apixaban).<br />&bull; If you use medicines called corticosteroids (e.g. prednisone).<br />&bull; If you are using Joswe Flamex at the same time as other non-acetylsalicylic NSAIDs such as ibuprofen or diclofenac. The use of these medicines together should be avoided.<br />&bull; If you smoke, have diabetes, raised blood pressure or raised cholesterol.<br />&bull; If your heart, liver or kidneys are not working well your doctor may want to keep a regular check on you.<br />&bull; If you have fluid retention (such as swollen ankles and feet).<br />&bull; If you are dehydrated, for instance due to sickness, diarrhoea or the use of diuretics (used to treat excess fluid in the body).<br />&bull; If you have had a serious allergic reaction or a serious skin reaction to any medicines.<br />&bull; If you feel ill due to an infection or think you have an infection, as Flamex may mask a fever or other signs of infection and inflammation.<br />&bull; If you are over 65 years of age your doctor will want to monitor you regularly.<br />&bull; The consumption of alcohol and NSAIDs may increase the risk of gastrointestinal problems.<br />As with other NSAIDs (e.g. ibuprofen or diclofenac) this medicine may lead to an increase in blood pressure, and so your doctor may ask to monitor your blood pressure on a regular basis.<br />Some cases of severe liver reactions, including severe liver inflammation, liver damage, liver failure (some with fatal outcome or requiring liver transplant), have been reported with Celecoxib. Of the cases that reported time to onset, most severe liver reactions occurred within one month of start of treatment.<br />Flamex may make it more difficult to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have problems to become pregnant (see section on Pregnancy and breast-feeding).</p><p><strong>C. Taking other medicines:</strong><br />Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription.<br />This is especially important if you are taking:<br />&bull; Dextromethorphan (used to treat coughs).<br />&bull; ACE inhibitors, angiotensin II antagonists, beta blockers and diuretics (used for high blood pressure and heart failure).<br />&bull; Fluconazole and rifampicin (used to treat fungal and bacterial infections).<br />&bull; Warfarin or other warfarin like medicines (&ldquo;blood-thinning&rdquo; agents that reduce blood clotting) including newer medicines like apixaban.<br />&bull; Lithium (used to treat some types of depression).<br />&bull; Other medicines to treat depression, sleep disorders, high blood pressure or an irregular heartbeat.<br />&bull; Neuroleptics (used to treat some mental disorders).<br />&bull; Methotrexate (used to treat Rheumatoid Arthritis, psoriasis and leukaemia).<br />&bull; Carbamazepine (used to treat epilepsy/seizures and some forms of pain or depression).<br />&bull; Barbiturates (used to treat epilepsy/seizures and some sleep disorders).<br />&bull; Ciclosporin and tacrolimus (used for immune system suppression e.g. after transplants).<br />Flamex can be taken with low dose acetylsalicylic acid (75 mg or less daily).<br />Ask your doctor for advice before taking both medicines together.</p><p><strong>D. Taking Flamex with food and drink:</strong><br />Flamex is for oral use. The capsules can be taken at any time of the day, with or without food.</p><p><strong>E. Pregnancy, breast-feeding and fertility:</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Pregnancy:<br />Flamex must not be used by women who are pregnant or can become pregnant (i.e. women of child bearing potential who are not using adequate contraception) during ongoing treatment. If you become pregnant during treatment with Flamex you should discontinue the treatment and contact your doctor for alternative treatment.</p><p>Breast-feeding:<br />Flamex must not be used during breast-feeding.<br />Fertility:<br />NSAIDs, including Flamex, may make it more dicult to become pregnant. You should tell your doctor if you are planning to become pregnant or if you have problems becoming pregnant.</p><p><strong>F. Driving and using machines:</strong><br />You should be aware of how you react to Flamex before you drive or operate machinery. If you feel dizzy or drowsy after taking Flamex, do not drive or operate machinery until these effects wear off.<br /><strong>G. Important information about some of the ingredients of Flamex:</strong><br />Flamex contains Lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Flamex exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. If you think or feel that the effect of Flamex is too strong or too weak, talk to your doctor or pharmacist.<br />Your doctor will tell you what dose you should take. As the risk of side effects associated with heart problems may increase with dose and duration of use, it is important that you use the lowest dose that controls your pain and you should not take Flamex for longer than necessary to control symptoms.</p><p><strong>Taking this medicine:</strong></p><p>Flamex is for oral use. The capsules can be taken at any time of the day, with or without food. However, try to take each dose of Flamex at the same time each day.<br />If you have difficulty swallowing capsules: The entire capsule contents can be sprinkled onto a level teaspoon of semi-solid food (such as cool or room temperature applesauce, rice gruel, yogurt or mashed banana) and swallowed immediately with a drink approximately 240 ml of water.<br />To open the capsule, hold upright to contain the granules at the bottom then gently squeeze the top and twist to remove, taking care not to spill the contents. Do not chew or crush the granules.<br />Contact your doctor within two weeks of starting treatment if you do not experience any benefit.</p><p><strong>How much to take:</strong></p><p>For Osteoarthritis the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed.<br />The dose is usually:<br />One 200 mg capsule once a day; or<br />One 100 mg capsule twice a day.</p><p>For Rheumatoid Arthritis the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed.<br />The dose is usually:<br />One 100 mg capsule twice a day.</p><p>For Ankylosing Spondylitis the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed.<br />The dose is usually:<br />One 200 mg capsule once a day; or<br />One 100 mg capsule twice a day.</p><p>Kidney or liver problems: Make sure your doctor knows if you have liver or kidney problems as you may need a lower dose.<br />The elderly, especially those with a weight less than 50 kg: If you are over 65 years of age and especially if you weigh less than 50 kg, your doctor may want to monitor you more closely.<br />You should not take more than 400 mg per day.<br />Use in children: Flamex is for adults only, it is not for use in children.</p><p>A. If you take more Flamex than you should:<br />If you take more medicine than prescribed, stop using this medicine and contact your doctor. If it is not possible to talk to a doctor go to the nearest hospital emergency department and take the medicine package with you.<br />B. If you forget to take Flamex:<br />If you forget to take a capsule, take it as soon as you remember. Do not take a double dose to make up for a forgotten dose.<br />C. If you stop taking Flamex:<br />Suddenly stopping your treatment with Flamex may lead to your symptoms getting worse. Do not stop taking Flamex unless your doctor tells you to. Your doctor may tell you to reduce the dose over a few days before stopping completely.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Flamex can cause side effects, although not everybody gets them.<br /><strong>The side effects listed below were observed in arthritis patients who took Celecoxib. Side effects marked with an asterisk (*) are listed below at the higher frequencies that occurred in patients who took Celecoxib to prevent colon polyps. Patients in these studies took Celecoxib at high doses and for a long duration.</strong></p><p>If any of the following happen, stop taking Flamex and tell your doctor immediately:<br />&bull; If you have an allergic reaction such as skin rash, swelling of the face, wheezing or difficulty breathing.<br />&bull; If you have heart problems such as pain in the chest.<br />&bull; If you have severe stomach pain or any sign of bleeding in the stomach or intestines, such as passing black or blood stained stools, or vomiting blood.<br />&bull; If you have a skin reaction such as rash, blistering or peeling of the skin.<br />&bull; If you have liver failure (symptoms may include nausea (feeling sick), diarrhoea, jaundice (your skin or the whites of your eyes look yellow)).</p><p>Very common: may affect more than 1 in 10 people:<br />&bull; High blood pressure, including worsening of existing high blood pressure *.</p><p>Common: may affect up to 1 in 10 people:<br />&bull; Heart attack*.<br />&bull; Fluid build-up with swollen ankles, legs and/or hands.<br />&bull; Urinary infections.<br />&bull; Shortness of breath*, sinusitis (sinus inflammation, sinus infection, blocked or painful sinuses), blocked or runny nose, sore throat, coughs, colds, flu-like symptoms.<br />&bull; Dizziness, difficulty sleeping.<br />&bull; Vomiting*, stomach ache, diarrhoea, indigestion, wind.<br />&bull; Rash, itching.<br />&bull; Muscle stiffness.<br />&bull; Difficulty swallowing*.<br />&bull; Headache.<br />&bull; Nausea (feeling sick).<br />&bull; Painful joints.<br />&bull; Worsening of existing allergies.<br />&bull; Accidental injury.</p><p>Uncommon: may affect up to 1 in 100 people:<br />&bull; Stroke*.<br />&bull; Heart failure, palpitations (awareness of heart beat), fast heart rate.<br />&bull; Abnormalities in liver-related blood tests.<br />&bull; Abnormalities in kidney-related blood tests.<br />&bull; Anaemia (changes in red blood cells that can cause fatigue and breathlessness).<br />&bull; Anxiety, depression, tiredness, drowsiness, tingling sensations (pins and needles).<br />&bull; High levels of potassium in blood test results (can cause nausea (feeling sick), fatigue, muscle weakness or palpitations).<br />&bull; Impaired or blurred vision, ringing in the ears, mouth pain and sores, difficulty hearing*.<br />&bull; Constipation, burping, stomach inflammation (indigestion, stomach ache or vomiting), worsening of inflammation of the stomach or intestine.<br />&bull; Leg cramps.<br />&bull; Raised itchy rash (hives).<br />&bull; Eye inflammation.<br />&bull; Difficulty breathing.<br />&bull; Skin discolouration (bruising).<br />&bull; Chest pain (generalised pain not related to the heart).<br />&bull; Face swelling.</p><p>Rare: may affect up to 1 in 1,000 people:<br />&bull; Ulcers (bleeding) in the stomach, gullet or intestines; or rupture of the intestine (can cause stomach ache, fever, nausea, vomiting, intestinal blockage), dark or black stools, inflammation of the pancreas (can lead to stomach pain), inflammation of the gullet (oesophagus).<br />&bull; Low levels of sodium in the blood (a condition known as hyponatraemia).<br />&bull; Reduced number of white blood cells (which help to protect the body from infection) or blood platelets (increased chance of bleeding or bruising).<br />&bull; Difficulty coordinating muscular movements.</p><p>&bull; Feeling confused, changes in the way things taste.<br />&bull; Increased sensitivity to light.<br />&bull; Loss of hair.<br />&bull; Hallucinations.<br />&bull; Bleeding in the eye.<br />&bull; Acute reaction that may lead to lung inflammation.<br />&bull; Irregular heartbeat.<br />&bull; Flushing.<br />&bull; Blood clot in the blood vessels in the lungs. Symptoms may include sudden breathlessness, sharp pains when you breathe or collapse.<br />&bull; Bleeding of the stomach or intestines (can lead to bloody stools or vomiting), inflammation of the intestine or colon.<br />&bull; Severe liver inflammation (hepatitis). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills.<br />&bull; Acute kidney failure.<br />&bull; Menstrual disturbances.<br />&bull; Swelling of the face, lips, mouth, tongue or throat, or difficulty swallowing.</p><p>Very rare: may affect up to 1 in 10,000 people:<br />&bull; Serious allergic reactions (including potentially fatal anaphylactic shock).<br />&bull; Serious skin conditions such as Stevens-Johnson syndrome, exfoliative dermatitis and toxic epidermal necrolysis (can cause rash, blistering or peeling of the skin) and acute generalised exanthematous pustulosis (symptoms include the skin becoming red with swollen areas covered in numerous small pustules).<br />&bull; A delayed allergic reaction with possible symptoms such as rash, swelling of the face, fever, swollen glands, and abnormal test results (e.g., liver, blood cell (eosinophilia, a type of raised white blood cell count)).<br />&bull; Bleeding within the brain causing death.<br />&bull; Meningitis (inflammation of the membrane around the brain and spinal cord).<br />&bull; Liver failure, liver damage and severe liver inflammation (fulminant hepatitis) (sometimes fatal or requiring liver transplant). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills.<br />&bull; Liver problems (such as cholestasis and cholestatic hepatitis, which may be accompanied by symptoms such as discoloured stools, nausea and yellowing of the skin or eyes).<br />&bull; Inflammation of the kidneys and other kidney problems (such as nephrotic syndrome and minimal change disease, which may be accompanied by symptoms such as water retention (oedema), foamy urine, fatigue and a loss of appetite).<br />&bull; Worsening of epilepsy (possible more frequent and/or severe seizures).<br />&bull; Blockage of an artery or vein in the eye leading to partial or complete loss of vision.<br />&bull; Inflamed blood vessels (can cause fever, aches, purple blotches on the skin).<br />&bull; A reduction in the number of red and white blood cells and platelets (may cause tiredness, easy bruising, frequent nose bleeds and increased risk of infections).<br />&bull; Muscle pain and weakness.<br />&bull; Impaired sense of smell.<br />&bull; Loss of taste.</p><p>Not known: frequency cannot be estimated from the available data:<br />&bull; Decreased fertility in females, which is usually reversible on discontinuation of the medicine.</p><p><strong>In clinical studies not associated with arthritis or other arthritic conditions, where Celecoxib was taken at doses of 400 mg per day for up to 3 years, the following additional side effects have been observed:</strong></p><p>Common: may affect up to 1 in 10 people:<br />&bull; Heart problems: angina (chest pain).<br />&bull; Stomach problems: irritable bowel syndrome (can include stomach ache, diarrhoea, indigestion, wind).<br />&bull; Kidney stones (which may lead to stomach or back pain, blood in urine), difficulty passing urine.<br />&bull; Weight gain.</p><p>Uncommon: may affect up to 1 in 100 people:<br />&bull; Deep vein thrombosis (blood clot usually in the leg, which may cause pain, swelling or redness of the calf or breathing problems).<br />&bull; Stomach problems: stomach infection (which can cause irritation and ulcers of the stomach and intestines).<br />&bull; Lower limb fracture.<br />&bull; Shingles, skin infection, eczema (dry itchy rash), pneumonia (chest infection (possible cough, fever, difficulty breathing)).<br />&bull; Floaters in the eye causing blurred or impaired vision, vertigo due to inner ear troubles, sore, inflamed or bleeding gums, mouth sores.<br />&bull; Excessive urination at night, bleeding from piles/ haemorrhoids, frequent bowel movements.<br />&bull; Fatty lumps in skin or elsewhere, ganglion cyst (harmless swellings on or around joints and tendons in the hand or foot), difficulty speaking, abnormal or very heavy bleeding from the vagina, breast pain.<br />&bull; High levels of sodium in blood test results.</p><p>If any of the side effects gets serious, or if you notice any side effects not&nbsp; listed in this leaflet, talk to your doctor or pharmacist.</p><p><strong>To Report any side effect (s):</strong><br />Contact JOSWE Medical:<br />Saudipv@josweplant com</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />Email: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not use Flamex after the expiry date which is stated on the label and carton.<br />&bull; This medicinal product does not require any special storage conditions.<br />&bull; Do not use any Flamex pack that is damaged or shows signs of tampering.<br />&bull; Store below 30oC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each capsule of Flamex 200 contains 200mg of Celecoxib.<br />Each capsule of Flamex 400 contains 400mg of Celecoxib.<br />The other ingredients are:<br />Lactose Monohydrate, Sodium Lauryl Sulphate, Povidone K-30, Croscarmellose Sodium, Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: Capsules.
Pack size of Flamex: 10 & 30 Capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jordan Sweden Medical and Sterilization Company (Joswe-medical)<br />P.O. Box 851831 Amman 11185 Jordan<br />Tel: +962 6 5859765, +962 6 5728327<br />Fax: +962 6 5814526, +962 6 5728326<br />E-mail: joswe@go.com.jo<br />www.joswe.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 08/2023; Revision number R1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يستخدم فلامكس للتخلص من أعراض وآثار إلتهاب المفاصل الروماتيزمي، إلتهاب المفاصل، إلتهاب الفقار اللاصق.</p><p dir="RTL">ينتمي فلامكس إلى مجموعة من المنتجات الطبية تسمى مضادات الإلتهاب غير الستيرويدية (NSAID)، ينتمي خصيصاً إلى مجموعة فرعية تسمى مثبطات (COX-2).</p><p dir="RTL">يقوم جسمك بتصنيع البروستاغلاندين الذي قد يسبب الألم والإتهاب. يقوم جسمك بإنتاج كمية أكبر منها في حالة إلتهاب المفاصل الروماتيزمي وإلتهاب المفاصل. يعمل فلامكس على التقليل من إنتاج البروستاغلاندين، وبتالي يعمل على تخفيف الألم والإلتهاب.</p><p dir="RTL">يجب أن تتوقع أن يبدأ تأثير الدواء خلال ساعات من تناول الجرعة الأولى، ولكنك قد لا تشعر بالتحسن الكامل لعدة أيام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ&zwnj;. لا تتناول فلامكس:</strong></p><p dir="RTL">&bull; إذا كنت تعاني من حساسية ضد السيلوكوكسيب أو أي من مكونات هذا الدواء (مذكورة في قسم رقم 6).</p><p dir="RTL">&bull; إذا كنت تعاني من الحساسية ضد مجموعة الأدوية التي تسمى &quot;سلفوناميد&quot; (مثل بعض المضادات الحيوية المستخدمة لعلاج الإلتهابات).</p><p dir="RTL">&bull; إذا كنت تعاني حالياً من قرحة في المعدة أو الأمعاء، أو نزيف في المعدة أو الأمعاء.</p><p dir="RTL">&bull; اذا كان تناولك لحمض أسيتيل ساليسيليك أو غيرها من أدوية مضادات الإلتهاب ومسكنات الألم (NSAID) قد أدى إلى إصابتك بالربو، أورام حميدة بالأنف، احتقان شديد في الأنف، أو ردة فعل تحسسية مثل حكة، طفح جلدي، تورم في الوجه، و الشفاه، و اللسان أو الحلق، صعوبات في التنفس أو صفير.</p><p dir="RTL">&bull; إذا كنت حامل. عليك أن تناقشي مع طبيبك طريقة لمنع الحمل إذا كان بالإمكان أن تحملي خلال فترة العلاج.</p><p dir="RTL">&bull; إذا كنت مرضع.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض شديد في الكبد.</p><p dir="RTL">&bull; إذا كنت تعاني من مرض شديد في الكلى.</p><p dir="RTL">&bull; إذا كنت تعاني من إلتهاب في الأمعاء مثل إلتهاب القولون التقرحي، مرض كرون.</p><p dir="RTL">&bull; إذا كنت تعاني من فشل في عضلة القلب، مرض القلب الإفقاري، أو مرض الدماغ الوعائي، على سبيل المثال إذا تم تشخيصك بأنك مصاب بنوبة قلبية، سكتة دماغية، نوبة&nbsp; نقص التروية العابر (انخفاض مفاجئ في ضخ الدم إلى الدماغ؛ المعروف بإسم &quot;السكتة الدماغية المصغرة&quot;)، الذبحة الصدرية، أو انسداد في الأوعية الدموية الموصلة إلى القلب أو الدماغ.</p><p dir="RTL">&bull; إذا كنت تعاني أو قد عانيت سابقاً من مشاكل في الدورة الدموية (مرض الشرايين الطرفية) أو إذا كنت قد أجريت جراحة في شرايين الساقين.</p><p dir="RTL">لا تتناول هذا الدواء إذا كان أي مما سبق ينطبق عليك.</p><p dir="RTL">إذا لم تكن متأكدا، تحدث مع طبيبك أو الصيدلي قبل تناول فلامكس.</p><p dir="RTL"><strong>ب&zwnj;. أخذ الحيطة والحذر مع فلامكس:</strong></p><p dir="RTL">تحدث إلى الطبيب أو الصيدلاني قبل تناول فلامكس:</p><p dir="RTL">&bull; إذا كنت قد عانيت سابقاً من قرحة أو نزيف في المعدة أو الأمعاء.</p><p dir="RTL">(لا تتناول فلامكس إذا كنت تعاني حالياً من قرحة أو نزيف في المعدة أو الأمعاء).</p><p dir="RTL">&bull; إذا كنت تتناول حمض أسيتيل ساليلسيليك (حتى إذا كنت تتناول جرعة مخفّضة منه لأغراض حماية القلب).</p><p dir="RTL">&bull; إذا كنت تستخدم أدوية للتقليل من تخثر الدم (مثل الوارفارين / مضادات التخثر المشابهة للوارفارين أو مضادات التخثر الفموية الجديدة، مثل أبسكسابان).</p><p dir="RTL">&bull; إذا كنت تستخدم أدوية الكورتيكوستيرويد (مثل بريدنيسون).</p><p dir="RTL">&bull; إذا كنت تستخدم فلامكس بالتزامن مع استخدامك لغيره من الـ NSAIDs (عدا حمض أسيتيل ساليسليك) مثل الأيبوبروفين أو الديكلوفيناك. يجب الامتناع عن استخدام هذه الأدوية.</p><p dir="RTL">&bull; إذا كنت مدخن، مصاب بالسكري، ارتفاع ضغط الدم أو ارتفاع الكوليستيرول.</p><p dir="RTL">&bull; إذا كان قلبك ، الكبد أو الكلى لا تؤدي وظيفتها على أكمل وجه، من الممكن أن يطلب طبيبك منك إجراء فحوصات دورية.</p><p dir="RTL">&bull; إذا كنت تعاني من ارتجاع السوائل (مثل تورم الكاحل والقدم).</p><p dir="RTL">&bull; إذا كنت مصاب بالجفاف، على سبيل المثال بسبب إصابتك بمرض، إسهال، أو بسبب استخدامك لمدرات البول (التي تستخدم للتخلص من كميات السوائل الزائدة في الجسم).</p><p dir="RTL">&bull; إذا كنت تعاني من تفاعلات تحسسية خطيرة أو تحسس جلدي خطيرلأي دواء.</p><p dir="RTL">&bull; إذا كنت تشعر بالمرض بسبب إلتهاب أو تعتقد بأنك ستصاب بالإلتهاب، لأن فلامكس من الممكن أن يعمل على إخفاء علامات الإصابة بالإلتهاب والحمى.</p><p dir="RTL">&bull; إذا كان عمرك أكثر من 65 سنة سيكون طبيبك بحاجة إلى مراقبتك بشكل دوري.</p><p dir="RTL">&bull; استهلاك الكحول والـNSAID&nbsp; من الممكن أن يزيد من خطر الإصابة بمشاكل هضمية.</p><p dir="RTL">من الممكن أن يؤدي هذا الدواء كما هو الحال مع الــ NSAID&nbsp; الأخرى (مثل الأيبوبروفين أو الديكلوفيناك) إلى ارتفاع في ضغط الدم، وبالتالي قد&nbsp; يطلب منك الطبيب مراقبة ضغط دمك بشكل منتظم.</p><p dir="RTL">تم الإبلاغ عن بعض حالات إصابات الكبد الشديدة عند استخدام السيليكوكسيب، من ضمنها الإلتهاب الشديد في الكبد، تلف الكبد، فشل الكبد (وبعضها تكون قاتلة أو بحاجة الى زراعة كبد).</p><p dir="RTL">ومن الحالات التي تم التبليغ عنها وقت بداية ظهور هذه الأعراض، معظم إصابات الكبد الشديدة وتحدث خلال الشهر الأول من البدء بالعلاج.</p><p dir="RTL">من الممكن أن يجعل فلامكس حدوث الحمل أكثر صعوبة. يجب إخبار طبيبك إذا كنت تخططين للإنجاب أو إذا كان لديك مشاكل تمنعك من الإنجاب (انظر إلى القسم الخاص بالحمل والرضاعة).</p><p dir="RTL"><strong>ج&zwnj;. تناول أدوية أخرى:</strong></p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلاني إذا كنت تتناول أو تناولت مؤخراً أي أدوية أخرى، بما في ذلك الأدویة التي تم الحصول علیھا بدون وصفة طبیة.</p><p dir="RTL">هذا مهم خصوصا إذا كنت تتناول:</p><p dir="RTL">&bull; ديكستروميثورفان (المستخدم لعلاج السعال).</p><p dir="RTL">&bull; مثبطات ACE، angiotensin II antagonists، حاصرات بيتا، و مدرات البول (التي تستخدم لعلاج ضغط الدم المرتفع وفشل القلب).</p><p dir="RTL">&bull; فلوكونازول والريفامبيسين (تستخدم لعلاج الإلتهابات البكتيرية والفطرية).</p><p dir="RTL">&bull; الوارفارين والأدوية المشابهة للوارفارين (أدوية ترقق الدم التي تقلل تخثر الدم) و من ضمنها الأدوية الجديدة مثل أبيكسابان.</p><p dir="RTL">&bull; ليثيوم (يستخدم لعلاج بعض أنواع الإكتئاب).</p><p dir="RTL">&bull;أدوية أخرى لعلاج الإكتئاب، اضطرابات النوم، ارتفاع ضغط الدم أو نبض القلب غير المنتظم.</p><p dir="RTL">&bull; مهدئات الأعصاب (تستخدم لعلاج بعض الإضطرابات العقلية).</p><p dir="RTL">&bull; ميثوتريكسيت (يستخدم لعلاج إلتهاب المفاصل الروماتيزمي، الصدفية وسرطان الدم).</p><p dir="RTL">&bull; كاربامازيبين (يستخدم لعلاج الصرع / التشنجات وبعض مشاكل اضطراب النوم).</p><p dir="RTL">&bull; سيكلوسبورين وتاكروليمس (يستخدم لتثبيط جهاز المناعة بعد عمليات الزراعة).</p><p dir="RTL">من الممكن تناول فلامكس مع جرعة مخفّضة من حمض أسيتيل ساليسيليك (75ملغم أو أقل يومياً). استشر طبيبك قبل تناولك لهذين الدوائين مع بعضهما.</p><p dir="RTL"><strong>د&zwnj;. تناول فلامكس مع الطعام والشراب:</strong></p><p dir="RTL">يستخدم فلامكس عن طريق الفم. يمكن تناول هذه الكبسولات في أي وقت من اليوم، مع الطعام أو بدونه.</p><p dir="RTL"><strong>ه&zwnj;. الحمل، الإرضاع والخصوبة:</strong></p><p dir="RTL">إذا كنت حامل أو مرضع، تفكرين بالإنجاب أو تخططين له، استشيري طبيبك قبل تناولك لهذا الدواء.</p><p dir="RTL">الحمل:</p><p dir="RTL">يجب عدم استخدام فلامكس من قبل الحامل أو من الممكن أن تصبح حامل (على سبيل المثال النساء اللاتي لديهن فرصة للإنجاب ولا يستخدمن مانع حمل مناسب) خلال فترة العلاج. إذا حدث حمل خلال فترة العلاج باستخدام فلامكس يجب أن تتوقفي عن تناول العلاج و الإتصال مع طبيبك لإعطائك علاج بديل.</p><p dir="RTL">الرضاعة:</p><p dir="RTL">يجب عدم استخدام فلامكس خلال فترة الرضاعة الطبيعية.</p><p dir="RTL">الخصوبة:</p><p dir="RTL">الـ NSAIDs ومن ضمنها فلامكس، من الممكن أن تجعل حدوث الحمل أكثر صعوبة. يجب عليك إخبار الطبيب إذا كنت تخططين للإنجاب، أو إذا كنت تعانين من مشاكل في الإنجاب.</p><p dir="RTL"><strong>و&zwnj;. القيادة واستخدام الآلات:</strong></p><p dir="RTL">يجب أن تكون على وعي عن كيفية إستجابة جسمك لـفلامكس قبل القيادة أو تشغيل الآلات. إذا شعرت بالدوار أو النعاس بعد تناول فلامكس امتنع عن القيادة أو تشغيل الآلات حتى زوال هذا التأثير.</p><p dir="RTL"><strong>&nbsp;ز.&nbsp;&nbsp; معلومات هامة عن بعض مكونات فلامكس:</strong></p><p dir="RTL">يحتوي فلامكس على اللاكتوز. إذا أخبرك&nbsp; طبيبك بأنك من الممكن أن لا تتحمل بعض السكريات، اتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول فلامكس كما أخبرك الطبيب. قم بإستشارة&nbsp; طبيبك أو الصيدلاني إذا لم تكن متأكداً. إذا اعتقدت أو شعرت بأن فلامكس له تأثير قوي جداً أو ضعيف جداً، تحدث الى طبيبك أو الصيدلاني.</p><p dir="RTL">سيقوم طبيبك بإخبارك بالجرعة الواجب تناولها. لأن خطر الأعراض الجانبية المرتبطة بمشاكل القلب من الممكن أن تزداد بزيادة الجرعة أو مدة الإستخدام، كما أنه من الضروري أن تتناول أقل جرعة&nbsp; للسيطرة على الألم&nbsp; و يجب عليك عدم تناول فلامكس لفترة أطول من اللازم للسيطرة على الأعراض.</p><p dir="RTL"><strong>تناول هذا الدواء:</strong></p><p dir="RTL">يُعطى فلامكس عن طريق الفم. من الممكن تناول هذه الكبسولات في أي وقت من اليوم، مع الطعام أو بدونه. مع ذلك، حاول أن تتناول كل جرعة من فلامكس في نفس الوقت يوميا.</p><p dir="RTL">إذا كنت تشعر بصعوبة عند بلع الكبسولات: من الممكن أن تفرغ محتويات الكبسولة في ملعقة صغيرة من الأطعمة شبه الصلبة (مثل عصير التفاح البارد أو بنفس درجة حرارة الغرفة، عصيدة الأرز، اللبن أو الموز المهروس) ويتم بلعها مباشرة مع شرب 240 مل من الماء).</p><p dir="RTL">لفتح الكبسولة، قم بوضع الكبسولة بشكل طولي لتجميع الحبيبات في الجزء السفلي منها ومن ثم قم بالضغط على الجزء العلوي مع لفه لإزالته، آخذاً بعين الإعتبار عدم تسريب مكونات الكبسولة. لا تقم بمضغ الحبيبات أو طحنها.</p><p dir="RTL">قم بالتواصل مع طبيبك خلال أسبوعين من بدأ العلاج، إذا لم تلاحظ أي تحسن.</p><p dir="RTL">الجرعة التي يجب تناولها:</p><p dir="RTL">في حالة الإصابة بمرض إلتهاب المفاصل: الجرعة الموصى بها هي 200ملغم يومياً، يتم زيادتها من قبل الطبيب لتصل كحد أقصى إلى 400ملغم عند الحاجة.</p><p dir="RTL">الجرعة المعتادة:</p><p dir="RTL">&nbsp;كبسولة واحدة 200ملغم يومياً، أو</p><p dir="RTL">كبسولة واحدة 100ملغم مرتين في اليوم.</p><p dir="RTL">في حالة الإصابة بمرض إلتهاب المفاصل الروماتيزمي: الجرعة الموصى بها هي 200ملغم يومياً، يتم زيادتها من قبل الطبيب لتصل كحد أقصى إلى 400ملغم عند الحاجة.</p><p dir="RTL">&nbsp;الجرعة المعتادة:</p><p dir="RTL">كبسولة واحدة 100ملغم مرتين في اليوم.</p><p dir="RTL">في حالة الإصابة بمرض إلتهاب الفقار اللاصق: الجرعة الموصى بها هي 200ملغم يومياً، يتم زيادتها من قبل الطبيب لتصل كحد أقصى إلى 400ملغم عند الحاجة.</p><p dir="RTL">الجرعة المعتادة:</p><p dir="RTL">كبسولة واحدة 200ملغم يومياً، أو</p><p dir="RTL">كبسولة واحدة 100ملغم مرتين في اليوم.</p><p dir="RTL">في حالة الإصابة في مشاكل في الكلى أو الكبد: تأكد من أن طبيبك على علم بإصابتك بمشاكل في الكلى أو الكبد لأنه من الممكن أن تكون بحاجة إلى جرعة أقل.</p><p dir="RTL">كبار السن، وخصيصا الذين أوزانهم تقل عن 50كغم: إذا كان عمرك أكثر من 65 سنة وخصيصاً إذا كنت تزن أقل من 50كغ، قد يكون الطبيب بحاجة إلى مراقبتك بشكل أكبر.</p><p dir="RTL">يجب أن لا تتناول أكثر من 400ملغم يومياً.</p><p dir="RTL">الإستخدام من قبل الأطفال: فلامكس للبالغين فقط، ولا يجوز استخدامه من قبل الأطفال.</p><p dir="RTL"><strong>أ.&nbsp; إذا تناولت جرعة من فلامكس أكثر من اللازم:</strong></p><p dir="RTL">إذا تناولت أكثر من جرعة الدواء الموصوف، توقف عن استخدام هذا الدواء واتصل بطبيبك. إذا لم تتمكن من التحدث مع الطبيب، اذهب إلى أقرب قسم طوارئ في المستشفى و خذ الدواء معك.</p><p dir="RTL"><strong>ب.&nbsp; إذا نسيت تناول فلامكس:</strong></p><p dir="RTL">إذا نسيت تناول الكبسولة، قم بتناولها بأقرب وقت ممكن حال تذكرك لها، لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة.</p><p dir="RTL"><strong>ج.&nbsp; إذا توقفت عن تناول فلامكس:</strong></p><p dir="RTL">إذا توقفت فجأة عن تناول فلامكس من الممكن أن يؤدي ذلك إلى أن تصبح الأعراض أكثر سوءاً. لا تتوقف عن تناول فلامكس ما لم يخبرك الطبيب بذلك. من الممكن أن يخبرك الطبيب بخفض الجرعة لبضعة أيام قبل التوقف عن تناوله نهائياً.</p><p dir="RTL">إذا كان لديك أي استفسارات أخرى حول استخدام هذا الدواء، قم بسؤال الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، من الممكن أن يسبب فلامكس آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>الأعراض الجانبية المذكورة أدناه سوف تظهر على الأشخاص الذين يتناولون سيليكوكسيب ومصابين بإلتهاب المفاصل. الأعراض الجانبية المؤشر لها بالنجمة (*) مذكورة أدناه على أنها الأكثر تكراراً في المرضى الّذين يتناولون سيليكوكسيب بهدف منع حدوث أورام حميدة في القولون. الأشخاص في هذه الدراسات يتناولون سيليكوكسيب بجرعات عالية ولمدة زمنية طويلة.</strong></p><p dir="RTL">إذا أصابك أي من الأعراض التالية، توقف عن تناول فلامكس وقم بإخبار طبيبك فوراً:</p><p dir="RTL">&bull; إذا&nbsp; كنت تعاني من ردة فعل تحسسية مثل طفح جلدي، تورم في الوجه، صفير أو صعوبة في التنفس.</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل قلبية مثل ألم في الصدر.</p><p dir="RTL">&bull; إذا كنت تعاني من ألم شديد في المعدة أو أي علامات للنزيف في المعدة أو الأمعاء، مثل البراز الأسود أو الملطخ بالدماء، أو استفراغ دم.</p><p dir="RTL">&bull; إذا كنت تعاني من التحسس الجلدي مثل الطفح، تقرح أو تقشر الجلد.</p><p dir="RTL">&bull; إذا كنت تعتني من فشل الكبد (تتضمن هذه الأعراض الغثيان (الشعور بالمرض)، الإسهال، اليرقان (إصفرار في لون الجلد أو بياض العين)).</p><p dir="RTL">شائعة جداً: من الممكن أن تصيب أكثر من شخص لكل 10 أشخاص:</p><p dir="RTL">&bull; ارتفاع ضغط الدم، وذلك يتضمن ارتفاع ضغط الدم بشكل أسوء مما مضى*.</p><p dir="RTL">شائعة: من الممكن أن تصيب لغاية شخص لكل 10 أشخاص:</p><p dir="RTL">&bull; نوبة قلبية*.</p><p dir="RTL">&bull; تجمع السوائل مع تورم الكاحلين، الأقدام و/أو اليدين.</p><p dir="RTL">&bull; إلتهابات في الجهاز البولي.</p><p dir="RTL">&bull; ضيق التنفس*، إلتهاب الجيوب (إلتهاب الجيوب الأنفية، انسداد الجيوب أو جيوب أنفية مؤلمة)، انسداد أو سيلان الأنف، إلتهاب الحلق، السعال، الرشح، أعراض مشابهة للإنفلونزا.</p><p dir="RTL">&bull; الدوار، صعوبات النوم.</p><p dir="RTL">&bull; الإستفراغ*، ألم المعدة، إسهال، عسر هضم، نفخة.</p><p dir="RTL">&bull; طفح جلدي، حكة.</p><p dir="RTL">&bull; تصلب في العضلات.</p><p dir="RTL">&bull; صعوبة في البلع*.</p><p dir="RTL">&bull; صداع.</p><p dir="RTL">&bull; الغثيان (الإحساس بالمرض).</p><p dir="RTL">&bull; ألم مفاصل.</p><p dir="RTL">&bull; تفاقم الحساسية.</p><p dir="RTL">&bull; إصابة عرضية.</p><p dir="RTL">غير شائعة: من الممكن أن تصيب لغاية شخص لكل من 100 شخص:</p><p dir="RTL">&bull; سكتة دماغية*.</p><p dir="RTL">&bull; فشل قلبي، الخفقان (الإحساس بضربات القلب)، تسارع نبض القلب.</p><p dir="RTL">&bull; فحوصات الدم المتعلقة بالكبد غير طبيعية.</p><p dir="RTL">&bull; فحوصات الدم المتعلقة بالكلى غير طبيعية.</p><p dir="RTL">&bull; فقر الدم (تغير في خلايا الدم الحمراء التي من الممكن أن تسبب تعب وضيق تنفس).</p><p dir="RTL">&bull; القلق، الإكتئاب، التعب، النعاس، الإحساس بالوخز (دبابيس و إبر).</p><p dir="RTL">&bull; ارتفاع مستوى البوتاسيوم في نتائج فحوصات الدم (من الممكن أن يؤدي إلى الغثيان (الشعور بالمرض)، التعب، ضعف في العضلات أو الخفقان).</p><p dir="RTL">&bull; ضعف البصر أو عدم وضوح الرؤية، طنين في الأذن، ألم وتقرحات في الفم، صعوبة في السمع*.</p><p dir="RTL">&bull; إمساك، التجشؤ، إلتهاب المعدة (عسر الهضم، ألم المعدة أو الإستفراغ)، تفاقم إلتهاب المعدة أو الأمعاء.</p><p dir="RTL">&bull; تشنجات الساق.</p><p dir="RTL">&bull; طفح جلدي يثير الحكة&nbsp; (شرى).</p><p dir="RTL">&bull; إلتهاب العين.</p><p dir="RTL">&bull; صعوبات تنفس.</p><p dir="RTL">&bull; تغيير لون الجلد (كدمات).</p><p dir="RTL">&bull; ألم في الصدر (ألم عام ليس له علاقة بالقلب).</p><p dir="RTL">&bull; تورم الوجه.</p><p dir="RTL">نادرة: من الممكن أن تصيب لغاية شخص لكل 1,000&nbsp; شخص:</p><p dir="RTL">&bull; تقرحات (نزيف) في المعدة، المريء أو الأمعاء، أو تمزق في الأمعاء (من الممكن أن يسبب ألم في المعدة، حمى، غثيان، استفراغ، انسداد في الأمعاء)، براز غامق اللون أو أسود، إلتهاب في البنكرياس ( من الممكن أن يسبب ألم في المعدة)، إلتهاب في المريء.</p><p dir="RTL">انخفاض مستوى الصوديوم في الدم (تعرف هذه الحالة بنقص صوديوم الدم).</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم البيضاء (التي تساعد على حماية الجسم من الإصابة بالإلتهاب)، أو الصفائح الدموية (الذي يزيد من إحتمالية حدوث النزيف أو الكدمات).</p><p dir="RTL">&bull; صعوبة في تنسيق الحركات العضلية.</p><p dir="RTL">&bull; الإحساس بالتشويش، تغير في مذاق الأشياء.</p><p dir="RTL">&bull; زيادة الحساسية للضوء.</p><p dir="RTL">&bull; تساقط الشعر.</p><p dir="RTL">&bull; الهلوسة.</p><p dir="RTL">&bull; نزيف في العين.</p><p dir="RTL">&bull; التفاعلات الحادة التي من الممكن أن تؤدي إلى التهاب الرئة.</p><p dir="RTL">&bull; نبضات قلب غير طبيعية.</p><p dir="RTL">&bull; التوهج.</p><p dir="RTL">&bull; تجلط الدم في الأوعية الدموية للرئة. الأعراض قد تشمل ضيق نفس مفاجئ، آلام حادة عند أخذ النفس أو تدهورفي الحالة الصحية.</p><p dir="RTL">&bull; نزيف في المعدة أو الأمعاء (من الممكن أن تؤدي الى براز ملطّخ بالدم أو الإستفراغ)، إلتهاب في الأمعاء أو القولون.</p><p dir="RTL">&bull; إلتهاب شديد في الكبد (مرض إلتهاب الكبد)، الأعراض ممكن أن تتضمن الغثيان (الإحساس بالمرض)، الإسهال، اليرقان (إصفرار في لون الجلد أو بياض العين)، بول غامق اللون، براز باهت اللون، سهولة حدوث النزيف، حكة أو قشعريرة.</p><p dir="RTL">&bull; الفشل الكلوي الحاد.</p><p dir="RTL">&bull; اضطرابات في الدورة الشهرية.</p><p dir="RTL">&bull; تورم في الوجه، الشفاه، الفم، اللسان أو الحلق، أو صعوبة في البلع.</p><p dir="RTL">نادرة جداً: من الممكن أن تصيب لغاية شخص لكل 10,000 شخص:</p><p dir="RTL">&bull; تفاعلات تحسسية حادة ( تشمل صدمة الحساسية القاتلة).</p><p dir="RTL">&bull; حالات مرضية حادة في الجلد مثل متلازمة ستيفنز جونز،التهاب الجلد المتقشر وانحلال البشرة السمي (من الممكن أن يسبب طفح جلدي، تقرح أو تقشر الجلد) البثار الطفحي العام الحاد ( الأعراض تشمل احمرار الجلد مع تورم بعض المناطق التي تكون مغطاة بالعديد من البثور الصددية الصغيرة).</p><p dir="RTL">&bull; تفاعلات تحسسية تظهر بشكل متأخر مع احتمالية ظهور بعض الأعراض مثل الطفح، تورم في الوجه، حمى، تورم في الغدد، نتائج فحوصات غير طبيعية (مثل الكبد، خلايا الدم (إيزينوفيليا نوع من أنواع فرط عدد خلايا الدم البيضاء)).</p><p dir="RTL">&bull; نزيف دماغي يؤدي إلى الوفاة.</p><p dir="RTL">&bull; إلتهاب السحايا (إلتهاب في الغشاء المحيط بالدماغ أو الحبل الشوكي).</p><p dir="RTL">&bull; فشل في الكبد، تلف في الكبد و إلتهابات الكبد الحادة (إلتهاب الكبد المداهم) (يكون قاتل في بعض الأوقات أو يحتاج إلى زراعة الكبد). الأعراض من الممكن أن تشمل الغثيان (الإحساس بالمرض)، الإسهال، اليرقان (إصفرار في لون الجلد أو بياض العين)، بول قاتم اللون، البراز الباهت، سهولة حدوث النزيف، الحكة أو القشعريرة.</p><p dir="RTL">&bull; مشاكل في الكبد (مثل الركود الصفراوي وإلتهاب الكبد الصفراوي، الذي من الممكن أن ترافقه أعراض مثل تغيير لون البراز، الغثيان وإصفرار لون الجلد أو بياض العين).</p><p dir="RTL">&bull; إلتهاب في الكلى أو غيرها من مشاكل الكلى (مثل المتلازمة الكلوية وأمراض التغييرات الطفيفة، التي من الممكن أن تصاحبها أعراض مثل ارتجاع الماء (وذمة)، بول رغوي، التعب وفقدان الشهية).</p><p dir="RTL">&bull; تفاقم مرض الصرع (تزيد من احتمالية تكرار التشنجات وشدتها).</p><p dir="RTL">&bull; انسداد في أحد شرايين أو أوردة العين مما يؤدي الى فقدان البصر الجزئي أو الكلي.</p><p dir="RTL">&bull; إلتهاب في الأوعية الدموية (الذي من الممكن أن يسبب الحمى، الألم، ظهوربقع ارجوانية اللون على الجلد).</p><p dir="RTL">&bull; انخفاض في عدد خلايا الدم الحمراء والبيضاء والصفائح الدموية (وهذا من الممكن أن يسبب الشعور بالتعب، سهولة الإصابة بالكدمات، نزيف أنفي متكرر وزيادة خطر الإصابة بالإلتهابات).</p><p dir="RTL">&bull; ألم وضعف في العضلات.</p><p dir="RTL">&bull; ضعف حاسة الشم.</p><p dir="RTL">&bull; فقدان حاسة التذوق.</p><p dir="RTL">غير معروفة: لا يمكن التنبؤ بتكرارها من البيانات المتاحة:</p><p dir="RTL">انخفاض مستوى الخصوبة لدى الإناث، وهذا بالعادة يعود إلى مستواه الطبيعي بعد التوقف عن استخدام الدواء.</p><p dir="RTL"><strong>في الدراسات السريرية التي لا تتعلق بإلتهاب المفاصل، إذا تم تناول سيليكوكسيب بجرعة 400ملغم يوميا لغاية 3سنوات، تم ملاحظة ظهور الأعراض الجانبية الإضافية التالية:</strong></p><p dir="RTL">شائعة: من الممكن أن تصيب لغاية شخص لكل 10 أشخاص:</p><p dir="RTL">&bull; مشاكل في القلب: الذبحة الصدرية (ألم في الصدر).</p><p dir="RTL">&bull; مشاكل في المعدة: متلازمة القولون العصبي (من الممكن أن تتضمن ألم في المعدة، إسهال، عسر هضم، نفخة).</p><p dir="RTL">&bull; حصى الكلى (التي من الممكن أن تسبب ألم في المعدة أو الظهر، دم مصاحب للبول)، عسر تبول.</p><p dir="RTL">&bull; زيادة الوزن.</p><p dir="RTL">غير شائعة: من الممكن أن تصيب لغاية شخص لكل 100 شخص:</p><p dir="RTL">&bull; جلطة (تجلط الدم عادة في الساق، مما قد يؤدي إلى الألم، ورم أو احمرار في ربلة الساق أو مشاكل تنفسية).</p><p dir="RTL">&bull; مشاكل في المعدة: إلتهابات المعدة (التي من الممكن أن تؤدي الى تهيج و قرحة في المعدة و الأمعاء).</p><p dir="RTL">&bull; كسور في الأطراف السفلية.</p><p dir="RTL">&bull; داء القوباء المنطقية، إلتهابات جلدية، إكزيما (طفح جلدي حكي جاف)، الإلتهاب الرئوي (إصابات الصدر (السعال، الحمى، صعوبة بالتنفس)).</p><p dir="RTL">&bull; ظهور شوائب أو عوالق في العين التي تسبب ضعف في البصر أو عدم وضوحه، الدوار بسبب مشاكل الأذن الداخلية، تقرحات، إلتهاب أو نزيف في اللثة، تقرحات فموية.</p><p dir="RTL">&bull; زيادة التبول ليلاً، نزيف من البواسير، حركة الأمعاء المتكررة.</p><p dir="RTL">&bull; كتل دهنية في الجلد أو أماكن أخرى، كتل عصبية (تورم مؤلم على أو حول المفاصل أو الأوتار في اليد أو القدم)، صعوبة في التكلم، نزيف شديد أو غير طبيعي من المهبل، ألم في الصدر.</p><p dir="RTL">&bull; إرتفاع في مستوى الصوديوم في نتائج فحوصات الدم.</p><p dir="RTL">إذا تفاقم أحد هذه الآثار الجانبية أو لاحظت أي آثار جانبية غير مذكورة في هذه النشرة، تحدث مع الطبيب أو الصيدلاني.</p><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p dir="RTL">التواصل مع الشركة الاردنية السويدية للمنتجات الطبية و التعقيم:</p><p dir="RTL">Saudipv@josweplant.com</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">&nbsp;المركز الوطني للتيقظ و السلامة الدوائية</p><p dir="RTL">&nbsp;فاكس: +966-11-205-7662</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">&nbsp;الايميل: npc.drug@sfda.gov.sa</p><p dir="RTL">&nbsp;الموقع الإلكتروني:&nbsp;https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; يحفظ بعيداً عن متناول الأطفال.</p><p dir="RTL">&bull; لا تستخدم فلامكس بعد انتهاء فترة الصلاحية&nbsp; المذكورة على اللاصق الداخلي و العبوة الخارجية.</p><p dir="RTL">&bull; لا يتطلب هذا المنتج الدوائي أي ظروف تخزين خاصة.</p><p dir="RTL">&bull; لا تستخدم فلامكس عند ملاحظة أي علامة تلف عليه.</p><p dir="RTL">&bull; يحفظ بدرجة حرارة أقل من 30 درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كل كبسولة من فلامكس 200 تحتوي على 200 ملغم سيليكوكسيب.</p><p dir="RTL">كل كبسولة من فلامكس 400 تحتوي على 400 ملغم سيليكوكسيب.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">لاكتوز أحادي الماء، سلفات لوريل الصوديوم، بوفيدون ك-30، صوديوم كروس كارميلوز، ستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشكل الصيدلاني: كبسولات.</p><p dir="RTL">حجم عبوة فلامكس: 10 كبسولات و 30 كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة الأردنية السويدية للمنتجات الطبية و التعقيم.</p><p dir="RTL">صندوق بريد 851831&nbsp; عمان 11185&nbsp; الأردن</p><p dir="RTL">هاتف: &nbsp;+962 6 5728327 , + 962 6 5859765</p><p dir="RTL">فاكس: &nbsp;+962 6 5728326 ،+962 6 5814526</p><p dir="RTL">الايميل: joswe@go.com.jo</p><p>www.joswe.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في  09/2023 ؛ رقم المراجعة R1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Flamex® 200 Capsule.
Flamex® 400 Capsule.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Flamex® 200 Capsule: One capsule contains 200mg of Celecoxib.
Flamex® 400 Capsule: One capsule contains 400mg of Celecoxib.

For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Flamex </strong>is indicated in adults for the symptomatic relief in the treatment of Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis.</p><p>The decision to prescribe a selective cyclooxygenase-2 (COX-2) inhibitor should be based on an assessment of the individual patient&#39;s overall risks (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology:</strong></p><p>As the cardiovascular risks of Celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1).</p><p><em><u>Osteoarthritis</u></em></p><p>The usual recommended daily dose is 200 mg taken once daily or in two divided doses. In some patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p><em><u>Rheumatoid arthritis</u></em></p><p>The initial recommended daily dose is 200 mg taken in two divided doses. The dose may, if needed, later be increased to 200 mg twice daily. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p><em><u>Ankylosing spondylitis</u></em></p><p>The recommended daily dose is 200 mg taken once daily or in two divided doses. In a few patients, with insufficient relief from symptoms, an increased dose of 400 mg once daily or in two divided doses may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p>The maximum recommended daily dose is 400 mg for all indications.</p><p><u>Special populations</u></p><p><em><u>Elderly (&gt;65 years)</u></em></p><p>As in younger adults, 200 mg per day should be used initially. The dose may, if needed, later be increased to 200 mg twice daily. Particular caution should be exercised in elderly with a body weight less than 50 kg. (See sections 4.4 and 5.2).</p><p><em><u>Paediatric population</u></em></p><p>Celecoxib is not indicated for use in children.</p><p><em><u>CYP2C9 poor metabolisers</u></em></p><p>Patients who are known, or suspected to be CYP2C9 poor metabolisers based on genotyping or previous history/experience with other CYP2C9 substrates should be administered Celecoxib with caution as the risk of dose-dependent adverse effects is increased. Consider reducing the dose to half the lowest recommended dose (see section 5.2).</p><p><em><u>Hepatic impairment</u></em></p><p>Treatment should be initiated at half the recommended dose in patients with established moderate liver impairment with a serum albumin of 25-35 g/l. Experience in such patients is limited to cirrhotic patients (see sections 4.3, 4.4 and 5.2).</p><p><em><u>Renal impairment</u></em></p><p>Experience with Celecoxib in patients with mild or moderate renal impairment is limited, therefore such patients should be treated with caution. (See sections 4.3, 4.4 and 5.2).</p><p><strong>Method of administration:</strong></p><p>Oral use.</p><p><strong>Flamex </strong>may be taken with or without food. For patients who have difficulty swallowing capsules, the contents of a Celecoxib capsule can be added to applesauce, rice gruel, yogurt or mashed banana. To do so, the entire capsule contents must be carefully emptied onto a level teaspoon of cool or room temperature applesauce, rice gruel, yogurt or mashed banana and should be ingested immediately with 240 ml of water. The sprinkled capsule contents on applesauce, rice gruel or yogurt are stable for up to 6 hours under refrigerated conditions (2-8&deg;C). The sprinkled capsule contents on mashed banana should not be stored under refrigerated conditions and should be ingested immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Known hypersensitivity to sulphonamides.
Active peptic ulceration or gastrointestinal (GI) bleeding.
Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid (aspirin) or other NSAIDs including COX-2 inhibitors.
In pregnancy and in women of childbearing potential unless using an effective method of contraception (see section 4.6).
Celecoxib has been shown to cause malformations in the two animal species studied (see sections 4.6 and 5.3). The potential for human risk in pregnancy is unknown, but cannot be excluded.
Breast-feeding (see sections 4.6 and 5.3).
Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).
Patients with estimated creatinine clearance <30 ml/min.
Inflammatory bowel disease.
Congestive heart failure (NYHA II-IV).
Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gastrointestinal (GI) effects</u></p><p>Upper and lower gastrointestinal complications [perforations, ulcers or bleedings (PUBs)], some of them resulting in fatal outcome, have occurred in patients treated with Celecoxib. Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly, glucocorticoids, patients using alcohol, or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.</p><p>urther increase in the risk of gastrointestinal adverse effects for Celecoxib (gastrointestinal ulceration or other gastrointestinal complications), when Celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses).</p><p>A significant difference in GI safety between selective COX-2 inhibitors + acetylsalicylic acid vs. NSAIDs + acetylsalicylic acid has not been demonstrated in long-term clinical trials (see section 5.1).</p><p><u>Concomitant NSAID use</u></p><p>The concomitant use of Celecoxib and a non-aspirin NSAID should be avoided.</p><p><u>Cardiovascular effects</u></p><p>Increased number of serious cardiovascular events, mainly myocardial infarction, has been found in a long-term placebo controlled study in subjects with sporadic adenomatous polyps treated with Celecoxib at doses of 200 mg BID and 400 mg BID compared to placebo (see section 5.1).</p><p>The cardiovascular risks of Celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.2, 4.3, 4.8 and 5.1).</p><p>Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, and smoking) should only be treated with Celecoxib after careful consideration (see section 5.1).</p><p>COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects. Therefore, antiplatelet therapies should not be discontinued (see section 5.1).</p><p><u>Fluid retention and oedema</u></p><p>As with other drugs known to inhibit prostaglandin synthesis, fluid retention and oedema have been observed in patients taking Celecoxib. Therefore, Celecoxib should be used with caution in patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing oedema from any other reason, since prostaglandin inhibition may result in deterioration of renal function and fluid retention. Caution is also required in patients taking diuretic treatment or otherwise at risk of hypovolaemia.</p><p><u>Hypertension</u></p><p>As with all NSAIDS, Celecoxib can lead to the onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of cardiovascular events. Therefore, blood pressure should be monitored closely during the initiation of therapy with Celecoxib and throughout the course of therapy.</p><p><u>Hepatic and renal effects</u></p><p>Compromised renal or hepatic function and especially cardiac dysfunction are more likely in the elderly and therefore medically appropriate supervision should be maintained.</p><p>NSAIDs, including Celecoxib, may cause renal toxicity. Clinical trials with Celecoxib have shown renal effects similar to those observed with comparator NSAIDs. Patients at greatest risk for renal toxicity are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, ACE-inhibitors, angiotensin II receptor antagonists, and the elderly (see section 4.5). Such patients should be carefully monitored while receiving treatment with Celecoxib.</p><p>Some cases of severe hepatic reactions, including fulminant hepatitis (some with fatal outcome), liver necrosis and, hepatic failure (some with fatal outcome or requiring liver transplant), have been reported with Celecoxib. Among the cases that reported time to onset, most of the severe adverse hepatic events developed within one month after initiation of Celecoxib treatment (see section 4.8).</p><p>If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of Celecoxib therapy should be considered.</p><p><u>CYP2D6 inhibition</u></p><p>Celecoxib inhibits CYP2D6. Although it is not a strong inhibitor of this enzyme, a dose reduction may be necessary for individually dose-titrated drugs that are metabolised by CYP2D6 (see section 4.5).</p><p><u>CYP2C9 poor metabolisers</u></p><p>Patients known to be CYP2C9 poor metabolisers should be treated with caution (see section 5.2).</p><p><u>Skin and systemic hypersensitivity reactions</u></p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of Celecoxib (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Serious hypersensitivity reactions (including anaphylaxis, angioedema and drug rash with eosinophilia and systemic symptoms (DRESS), or hypersensitivity syndrome), have been reported in patients receiving Celecoxib (see section 4.8). Patients with a history of sulphonamide allergy or any drug allergy may be at greater risk of serious skin reactions or hypersensitivity reactions (see section 4.3). Celecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p><u>General</u></p><p>Celecoxib may mask fever and other signs of inflammation.</p><p><u>Use with oral anticoagulants</u></p><p>In patients on concurrent therapy with warfarin, serious bleeding events, some of them fatal, have been reported. Increased prothrombin time (INR) with concurrent therapy has been reported.</p><p>Therefore, this should be closely monitored in patients receiving warfarin / coumarin-type oral anticoagulants, particularly when therapy with Celecoxib is initiated or Celecoxib dose is changed (see section 4.5). Concomitant use of anticoagulants with NSAIDS may increase the risk of bleeding. Caution should be exercised when combining Celecoxib with warfarin or other oral anticoagulants, including novel anticoagulants (e.g. apixaban, dabigatran, and rivaroxaban).</p><p><u>Excipients</u></p><p>Flamex&reg; Capsules contain Lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacodynamic interactions:</strong></p><p>Anticoagulants</p><p>Anticoagulant activity should be monitored particularly in the first few days after initiating or changing the dose of Celecoxib in patients receiving warfarin or other anticoagulants since these patients have an increased risk of bleeding complications.</p><p>Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with Celecoxib is initiated or the dose of Celecoxib is changed (see section 4.4). Bleeding events in association with increases in prothrombin time have been reported, predominantly in the elderly, in patients receiving Celecoxib concurrently with warfarin, some of them fatal.</p><p>Anti-hypertensives</p><p>NSAIDs may reduce the effect of anti-hypertensive medicinal products including ACE-inhibitors, angiotensin II receptor antagonists, diuretics and beta-blockers. As for NSAIDs, the risk of acute renal insufficiency, which is usually reversible, may be increased in some patients with compromised renal function (e.g. dehydrated patients, patients on diuretics, or elderly patients) when ACE inhibitors, angiotensin II receptor antagonists, and/or diuretics are combined with NSAIDs, including Celecoxib (see section 4.4). Therefore, the combination should be administered with caution, especially in the elderly.</p><p>Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>In a 28-day clinical study in patients with lisinopril-controlled Stage I and II hypertension, administration of Celecoxib 200 mg BID resulted in no clinically significant increases, when compared to placebo treatment, in mean daily systolic or diastolic blood pressure as determined using 24-hour ambulatory blood pressure monitoring. Among patients treated with Celecoxib 200 mg BID, 48% were considered unresponsive to lisinopril at the final clinic visit (defined as either cuff diastolic blood pressure &gt;90 mmHg or cuff diastolic blood pressure increased &gt;10% compared to baseline), compared to 27% of patients treated with placebo; this difference was statistically significant.</p><p><u>Ciclosporin and Tacrolimus</u></p><p>Coadministration of NSAIDs and Ciclosporin or tacrolimus may increase the nephrotoxic effect of Ciclosporin or tacrolimus, respectively. Renal function should be monitored when Celecoxib and any of these drugs are combined.</p><p><u>Acetylsalicylic acid</u></p><p>Celecoxib can be used with low-dose acetylsalicylic acid but is not a substitute for acetylsalicylic acid for cardiovascular prophylaxis. In the submitted studies, as with other NSAIDs, an increased risk of gastrointestinal ulceration or other gastrointestinal complications compared to use of Celecoxib alone was shown for concomitant administration of low-dose acetylsalicylic acid (see section 5.1).</p><p><strong>Pharmacokinetic interactions:</strong></p><p><u>Effects of Celecoxib on other drugs</u></p><p><em>CYP2D6 Inhibition</em></p><p>Celecoxib is an inhibitor of CYP2D6. The plasma concentrations of drugs that are substrates of this enzyme may be increased when Celecoxib is used concomitantly. Examples of drugs which are metabolised by CYP2D6 are antidepressants (tricyclics and SSRIs), neuroleptics, antiarrhythmic drugs, etc. The dose of individually dose-titrated CYP2D6 substrates may need to be reduced when treatment with Celecoxib is initiated or increased if treatment with Celecoxib is terminated.</p><p>Concomitant administration of Celecoxib 200 mg twice daily resulted in 2.6-fold and 1.5-fold increases in plasma concentrations of dextromethorphan and metoprolol (CYP2D6 substrates), respectively. These increases are due to Celecoxib CYP2D6 inhibition of the CYP2D6 substrate metabolism.</p><p><em>CYP2C19 Inhibition</em></p><p><em>In vitro </em>studies have shown some potential for Celecoxib to inhibit CYP2C19 catalysed metabolism. The clinical significance of this in vitro finding is unknown. Examples of drugs which are metabolised by CYP2C19 are diazepam, citalopram and imipramine.</p><p><em>Methotrexate</em></p><p>In patients with rheumatoid arthritis Celecoxib had no statistically significant effect on the pharmacokinetics (plasma or renal clearance) of methotrexate (in rheumatologic doses). However, adequate monitoring for methotrexate-related toxicity should be considered when combining these two drugs.</p><p><em>Lithium</em></p><p>In healthy subjects, co-administration of Celecoxib 200 mg twice daily with 450 mg twice daily of lithium resulted in a mean increase in C of 16% and in AUC of 18% of lithium. Therefore, patients on lithium treatment should be closely monitored when Celecoxib is introduced or withdrawn.</p><p><em>Oral contraceptives</em></p><p>In an interaction study, Celecoxib had no clinically relevant effects on the pharmacokinetics of oral contraceptives (1 mg norethisterone /35 micrograms ethinylestradiol).</p><p><em>Glibenclamide/tolbutamide</em></p><p>Celecoxib does not affect the pharmacokinetics of tolbutamide (CYP2C9 substrate), or</p><p>glibenclamide to a clinically relevant extent.</p><p><u>Effects of other drugs on Celecoxib</u></p><p><em>CYP2C9 Poor Metabolisers</em></p><p>In individuals who are CYP2C9 poor metabolisers and demonstrate increased systemic exposure to Celecoxib, concomitant treatment with CYP2C9 inhibitors such as fluconazole could result in further increases in Celecoxib exposure. Such combinations should be avoided in known CYP2C9 poor metabolisers (see sections 4.2 and 5.2).</p><p><em>CYP2C9 Inhibitors and Inducers</em></p><p>Since Celecoxib is predominantly metabolised by CYP2C9 it should be used at half the recommended dose in patients receiving fluconazole. Concomitant use of 200 mg single dose of Celecoxib and 200 mg once daily of fluconazole, a potent CYP2C9 inhibitor, resulted in a mean increase in Celecoxib C of 60% and in AUC of 130%. Concomitant use of inducers of</p><p>CYP2C9 such as rifampicin, carbamazepine and barbiturates may reduce plasma concentrations of Celecoxib.</p><p><em>Ketoconazole and Antacids</em></p><p>Ketoconazole or antacids have not been observed to affect the pharmacokinetics of Celecoxib.</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Studies in animals (rats and rabbits) have shown reproductive toxicity, including malformations (see sections 4.3 and 5.3).</p><p>Inhibition of prostaglandin synthesis might adversely affect pregnancy. Data from epidemiological studies suggest an increased risk of spontaneous abortion after use of prostaglandin synthesis inhibitors in early pregnancy. The potential for human risk in pregnancy is unknown, but cannot be excluded. Celecoxib, as with other drugs inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester. Celecoxib is contraindicated in pregnancy and in women who can become pregnant (see sections 4.3 and 4.4). If a woman becomes pregnant during treatment, Celecoxib should be discontinued.</p><p><u>Breast-feeding</u></p><p>Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma.</p><p>Administration of Celecoxib to a limited number of lactating women has shown a very low transfer of Celecoxib into breast milk. Women who take Celecoxib should not breastfeed.</p><p><u>Fertility</u></p><p>Based on the mechanism of action, the use of NSAIDs, including Celecoxib, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience dizziness, vertigo or somnolence while taking Celecoxib should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are listed by system organ class and ranked by frequency in Table 1, reflecting data from the following sources:</p><p>&bull; Adverse reactions reported in osteoarthritis patients and rheumatoid arthritis patients at incidence rates greater than 0.01% and greater than those reported for placebo during 12 placeboand/ or active-controlled clinical trials of duration up to 12 weeks at Celecoxib daily doses from 100 mg up to 800 mg. In additional studies using non-selective NSAID comparators, approximately 7400 arthritis patients have been treated with Celecoxib at daily doses up to 800 mg, including approximately 2300 patients treated for 1 year or longer. The adverse reactions observed with Celecoxib in these additional studies were consistent with those for osteoarthritis and rheumatoid arthritis patients listed in Table 1.</p><p>&bull; Adverse reactions reported at incidence rates greater than placebo for subjects treated with</p><p>Celecoxib 400 mg daily in long-term polyp prevention trials of duration up to 3 years (the</p><p>Adenoma Prevention with Celecoxib (APC) and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials; see section 5.1, Pharmacodynamic properties: Cardiovascular safety &ndash; long-term studies involving patients with sporadic adenomatous polyps).</p><p>&bull; Adverse drug reactions from post-marketing surveillance as spontaneously reported during a period in which an estimated &gt;70 million patients were treated with Celecoxib (various doses, durations, and indications). Even though these were identified as reactions from post-marketing reports, trial data were consulted to estimate frequency. Frequencies are based on a cumulative meta-analysis with pooling of trials representing exposure in 38102 patients.</p><p>Table 1. Adverse Drug Reactions in Celecoxib Clinical Trials and Surveillance Experience</p><p>(MedDRA Preferred Terms)<sup>1,2</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p><strong>Adverse Drug Reaction Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ</strong></p><p><strong>Class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p><p><strong>(&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge;1/100</strong></p><p><strong>to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1,000</strong></p><p><strong>to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;1/10,000</strong></p><p><strong>to &lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p><strong>(&lt;1/10,000)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p><p><strong>Not</strong></p><p><strong>Known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and</strong></p><p><strong>infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Sinusitis, upper</p><p>respiratory tract</p><p>infection,</p><p>pharyngitis,</p><p>urinary</p><p>tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and</strong></p><p><strong>lymphatic</strong></p><p><strong>system</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Leukopenia,</p><p>thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Pancytopenia<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Anaphylactic</p><p>Shock<sup>4</sup>,</p><p>anaphylactic</p><p>Reaction<sup>4</sup>)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and</strong></p><p><strong>nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Anxiety,</p><p>depression,</p><p>fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Confusional</p><p>state,</p><p>hallucinations<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Dizziness,</p><p>hypertonia,</p><p>headache<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Cerebral</p><p>Infarction<sup>1</sup>,</p><p>paraesthesia,</p><p>somnolence</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Ataxia,</p><p>dysgeusia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Haemorrhage</p><p>intracranial</p><p>(including fatal</p><p>intracranial</p><p>haemorrhage)<sup>4</sup>,</p><p>meningitis</p><p>aseptic<sup>4</sup>,</p><p>epilepsy</p><p>(including</p><p>aggravated</p><p>epilepsy)<sup>4</sup>,</p><p>ageusia<sup>4</sup>,</p><p>anosmia<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Vision blurred,</p><p>Conjunctivitis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Eye</p><p>Haemorrhage<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Retinal artery</p><p>Occlusion<sup>4</sup>,</p><p>retinal vein</p><p>occlusion<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and</strong></p><p><strong>labyrinth</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Tinnitus,</p><p>Hypoacusis<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Myocardial</p><p>Infarction<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Cardiac failure,</p><p>palpitations,</p><p>tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Arrhythmia<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hypertension<sup>1</sup></p><p>(including</p><p>aggravated</p><p>hypertension)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Pulmonary</p><p>embolism ,</p><p>flushing<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Vasculitis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory,</strong></p><p><strong>thoracic, and</strong></p><p><strong>mediastinal</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhinitis, cough,</p><p>dyspnoea1</p></td><td style="vertical-align:top"><p>Bronchospasm4</p></td><td style="vertical-align:top"><p>Pneumonitis4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Nausea ,</p><p>abdominal pain,</p><p>diarrhoea,</p><p>dyspepsia,</p><p>flatulence,</p><p>vomiting<sup>1</sup>,</p><p>dysphagia<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Constipation,</p><p>gastritis,</p><p>stomatitis,</p><p>gastrointestinal</p><p>inflammation</p><p>(including</p><p>aggravation of</p><p>gastrointestinal</p><p>inflammation),</p><p>eructation</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Gastrointestinal</p><p>Haemorrhage<sup>4</sup>,</p><p>duodenal ulcer,</p><p>gastric ulcer,</p><p>oesophageal</p><p>ulcer, intestinal</p><p>ulcer, and large</p><p>intestinal ulcer;</p><p>intestinal</p><p>perforation;</p><p>oesophagitis,</p><p>melaena;</p><p>pancreatitis,</p><p>colitis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Hepatobiliary</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Hepatic function</p><p>abnormal,</p><p>hepatic enzyme</p><p>increased</p><p>(including</p><p>increased</p><p>SGOT and</p><p>SGPT)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Hepatitis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Hepatic failure<sup>4</sup></p><p>(sometimes</p><p>fatal</p><p>or requiring</p><p>liver</p><p>transplant),</p><p>hepatitis</p><p>fulminant<sup>4</sup></p><p>(some</p><p>with fatal</p><p>outcome),</p><p>hepatic</p><p>necrosis4,</p><p>cholestasis<sup>4</sup>,</p><p>hepatitis</p><p>cholestatic<sup>4</sup>,</p><p>jaundice<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous</strong></p><p><strong>tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Rash, pruritus (includes</p><p>pruritus</p><p>generalised)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Urticaria, ecchymosis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Angioedema<sup>4</sup>, alopecia,</p><p>photosensitivity</p></td><td style="vertical-align:top"><p>Dermatitis exfoliative<sup>4</sup>,</p><p>erythema</p><p>multiforme<sup>4</sup>,</p><p>Stevens-</p><p>Johnson</p><p>syndrome<sup>4</sup>,</p><p>toxic</p><p>epidermal</p><p>necrolysis<sup>4</sup>,</p><p>drug</p><p>reaction with</p><p>eosinophilia and</p><p>systemic</p><p>symptoms</p><p>(DRESS)<sup>4</sup>,</p><p>acute</p><p>generalised</p><p>exanthematous</p><p>pustulosis</p><p>(AGEP)<sup>4</sup>,</p><p>dermatitis</p><p>bullous<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal</strong></p><p><strong>and connective</strong></p><p><strong>tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Arthralgia<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Muscle spasms</p><p>(leg cramps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Myositis<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Renal and</strong></p><p><strong>urinary</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Blood creatinine</p><p>increased, blood</p><p>urea increased</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Renal failure</p><p>Acute<sup>4</sup>,</p><p>hyponatraemia<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Tubulointerstiti</p><p>al Nephritis<sup>4</sup>,</p><p>nephrotic</p><p>syndrome<sup>4</sup>,</p><p>glomerulonephr</p><p>itis minimal</p><p>lesion<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive</strong></p><p><strong>system and</strong></p><p><strong>breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Menstrual</p><p>disorder<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Infertility</p><p>female (female</p><p>fertility</p><p>decreased)<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong></p><p><strong>disorders and</strong></p><p><strong>administrative</strong></p><p><strong>site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Influenza-like</p><p>illness, Oedema</p><p>peripheral/ fluid</p><p>retention</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Face oedema,</p><p>chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury,</strong></p><p><strong>poisoning and</strong></p><p><strong>procedural</strong></p><p><strong>complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Injury</p><p>(accidental</p><p>injury</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p>1: Adverse drug reactions that occurred in polyp prevention trials, representing subjects treated with</p><p>Celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the APC and PreSAP trials). The adverse drug reactions listed above for the polyp prevention trials are only those that have been previously recognized in the post-marketing surveillance experience, or have occurred more frequently than in the arthritis trials.</p><p>2: Furthermore, the following <em>previously unknown </em>adverse reactions occurred in polyp prevention trials,</p><p>representing subjects treated with Celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the</p><p>APC and PreSAP trials):</p><p>Common: angina pectoris, irritable bowel syndrome, nephrolithiasis, blood creatinine increased, benign prostatic hyperplasia, weight increased. Uncommon: helicobacter infection, herpes</p><p>zoster, erysipelas, bronchopneumonia, labyrinthitis, gingival infection, lipoma, vitreous floaters,</p><p>conjunctival haemorrhage, deep vein thrombosis, dysphonia, haemorrhoidal haemorrhage, frequent bowel movements, mouth ulceration, allergic dermatitis, ganglion, nocturia, vaginal haemorrhage, breast tenderness, lower limb fracture, blood sodium increased.</p><p>3: Women intending to become pregnant are excluded from all trials, thus consultation of the trial database for the frequency of this event was not reasonable.</p><p>4: Frequencies are based on cumulative meta-analysis with pooling of trials representing exposure in</p><p>38102 patients.</p></td></tr></tbody></table><p>In final data (adjudicated) from the APC and PreSAP trials in patients treated with Celecoxib 400 mg daily for up to 3 years (pooled data from both trials; see section 5.1 for results from individual trials), the excess rate over placebo for myocardial infarction was 7.6 events per 1000 patients (uncommon) and there was no excess rate for stroke (types not differentiated) over placebo.</p><p>To reports any side effect (s):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience of overdose. Single doses up to 1200 mg and multiple doses up to 1200 mg twice daily have been administered to healthy subjects for nine days without clinically significant adverse effects. In the event of suspected overdose, appropriate supportive medical care should be provided e.g. by eliminating the gastric contents, clinical supervision and, if necessary, the institution of symptomatic treatment. Dialysis is unlikely to be an efficient method of drug removal due to high protein binding.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Pharmacotherapeutic group: Non-steroidal anti-inflammatory and</p><p>antirheumatic drugs, NSAIDs, Coxibs, ATC code: M01AH01.</p><p><u>Mechanism of action</u></p><p>Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers.</p><p><u>Pharmacodynamic effects</u></p><p>Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified.</p><p>COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing.</p><p>COX-2 has been identified in tissue around gastric ulcers in human but its relevance to ulcer healing has not been established.</p><p>The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. COX-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.</p><p>Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differs from arylamine sulfonamides (e.g. sulfamethoxizole and other sulfonamide antibiotics).</p><p>A dose dependent effect on TxB2 formation has been observed after high doses of Celecoxib.</p><p>However, in healthy subjects, in small multiple dose studies with 600 mg BID (three times the highest recommended dose) Celecoxib had no effect on platelet aggregation and bleeding time compared to placebo.</p><p><u>Clinical efficacy and safety</u></p><p>Several clinical studies have been performed confirming efficacy and safety in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Celecoxib was evaluated for the treatment of the inflammation and pain of osteoarthritis of the knee and hip in approximately 4200 patients in placebo and active controlled trials of up to 12 weeks duration. It was also evaluated for treatment of the inflammation and pain of rheumatoid arthritis in approximately 2100 patients in placebo and active controlled trials of up to 24 weeks duration. Celecoxib at daily doses of 200 mg &ndash; 400 mg provided pain relief within 24 hours of dosing. Celecoxib was evaluated for the symptomatic treatment of ankylosing spondylitis in 896 patients in placebo and active controlled trials of up to 12 weeks duration. Celecoxib at doses of 100 mg BID, 200 mg QD, 200 mg BID and 400 mg QD in these studies demonstrated significant improvement in pain, global disease activity and function in Ankylosing spondylitis.</p><p>Five randomised double-blind controlled studies have been conducted including scheduled upper gastrointestinal endoscopy in approximately 4500 patients free from initial ulceration (Celecoxib doses from 50 mg &ndash; 400 mg BID). In twelve week endoscopy studies Celecoxib (100 &ndash; 800 mg per day) was associated with a significantly lower risk of gastroduodenal ulcers compared with naproxen (1000 mg per day) and ibuprofen (2400 mg per day). The data were inconsistent in comparison with diclofenac (150 mg per day). In two of the 12-week studies the percentage of patients with endoscopic gastroduodenal ulceration was not significantly different between placebo and Celecoxib 200 mg BID and 400 mg BID.</p><p>In a prospective long-term safety outcome study (6 to 15 month duration, CLASS study), 5,800 osteoarthritis and 2,200 rheumatoid arthritis patients received Celecoxib 400 mg BID (4-fold and 2-fold the recommended osteoarthritis and rheumatoid arthritis doses, respectively), ibuprofen 800 mg TID or diclofenac 75 mg BID (both at therapeutic doses).</p><p>Twenty-two percent of enrolled patients took concomitant low-dose acetylsalicylic acid (&le;325</p><p>mg/day), primarily for cardiovascular prophylaxis. For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or obstruction) Celecoxib was not significantly different than either ibuprofen or diclofenac individually. Also for the combined NSAID group there was no statistically significant difference for complicated ulcers (relative risk 0.77, 95 % CI</p><p>0.41-1.46, based on entire study duration). For the combined endpoint, complicated and symptomatic ulcers, the incidence was significantly lower in the Celecoxib group compared to the NSAID group, relative risk 0.66, 95% CI 0.45-0.97 but not between Celecoxib and diclofenac.</p><p>Those patients on Celecoxib and concomitant low-dose acetylsalicylic acid experienced 4 fold higher rates of complicated ulcers as compared to those on Celecoxib alone. The incidence of clinically significant decreases in haemoglobin (&gt;2 g/dL), confirmed by repeat testing, was significantly lower in patients on Celecoxib compared to the NSAID group, relative risk 0.29,</p><p>95% CI 0.17- 0.48. The significantly lower incidence of this event with Celecoxib was maintained with or without acetylsalicylic acid use.</p><p>In a prospective randomised 24 week safety study in patients who were aged &ge;60 years or had a history of gastroduodenal ulcers (users of ASA excluded), the percentages of patients with decreases in haemoglobin (&ge;2 g/dL) and/or haematocrit (&ge;10%) of defined or presumed GI origin were lower in patients treated with Celecoxib 200 mg twice daily (N=2238) compared to patients treated with diclofenac SR 75 mg twice daily plus omeprazole 20 mg once daily (N=2246) (0.2% vs. 1.1% for defined GI origin, p = 0.004; 0.4% vs. 2.4% for presumed GI origin, p = 0.0001). The rates of clinically manifest GI complications such as perforation, obstruction or haemorrhage were very low with no differences between the treatment groups (4-5 per group).</p><p><u>Cardiovascular safety &ndash; long-term studies involving subjects with sporadic adenomatous polyps</u></p><p>Two studies involving subjects with sporadic adenomatous polyps were conducted with Celecoxib i.e., the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps). In the APC trial, there was a dose-related increase in the composite endpoint of cardiovascular death, myocardial infarction, or stroke (adjudicated) with Celecoxib compared to placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint.</p><p>In the APC trial, the relative risks compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke were 3.4 (95% CI 1.4 - 8.5) with Celecoxib 400 mg twice daily and 2.8 (95% CI 1.1 - 7.2) with Celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects) respectively, compared to 0.9% (6/679 subjects) for placebo. The increases for both Celecoxib dose groups versus placebo were mainly due to an increased incidence of myocardial infarction.</p><p>In the PreSAP trial, the relative risk compared to placebo for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 - 2.4) with Celecoxib 400 mg once daily compared to placebo.</p><p>Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively. The incidence of myocardial infarction (adjudicated) was 1.0% (9/933 subjects) with Celecoxib 400 mg once daily and 0.6% (4/628 subjects) with placebo.</p><p>Data from a third long-term study, ADAPT (The Alzheimer&#39;s Disease Anti-inflammatory</p><p>Prevention Trial), did not show a significantly increased cardiovascular risk with Celecoxib 200 mg BID compared to placebo. The relative risk compared to placebo for a similar composite endpoint (cardiovascular death, myocardial infarction, stroke) was 1.14 (95% CI 0.61 - 2.12) with Celecoxib 200 mg twice daily. The incidence of myocardial infarction was 1.1% (8/717 patients) with Celecoxib 200 mg twice daily and 1.2% (13/1070 patients) with placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Celecoxib is well absorbed reaching peak plasma concentrations after approximately 2-3 hours.</p><p>Dosing with food (high fat meal) delays absorption of Celecoxib by about 1 hour resulting in a T of about 4 hours and increases bioavailability by about 20%.</p><p>In healthy adult volunteers, the overall systemic exposure (AUC) of Celecoxib was equivalent when Celecoxib was administered as intact capsule or capsule contents sprinkled on applesauce.</p><p>There were no significant alterations in C, T or T after administration of capsule contents on applesauce.</p><p><u>Distribution</u></p><p>Plasma protein binding is about 97 % at therapeutic plasma concentrations and the drug is not preferentially bound to erythrocytes.</p><p><u>Biotransformation</u></p><p>Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, inactive as COX-1 or COX-2 inhibitors, have been identified in human plasma i.e., a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate.</p><p>Cytochrome P450 2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*3 polymorphism.</p><p>In a pharmacokinetic study of Celecoxib 200 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*3/*3, the median C and AUC of Celecoxib on day 7 were approximately 4- fold and 7-fold, respectively, in subjects genotyped as CYP2C9*3/*3 compared to other genotypes. In three separate single dose studies, involving a total of 5 subjects genotyped as CYP2C9*3/*3, single-dose AUC increased by approximately 3- fold compared to normal metabolisers. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3-1.0% among different ethnic groups.</p><p>Patients who are known, or suspected to be CYP2C9 poor metabolisers based on previous history/experience with other CYP2C9 substrates should be administered Celecoxib with caution (see section 4.2).</p><p>No clinically significant differences were found in PK parameters of Celecoxib between elderly African-Americans and Caucasians.</p><p>The plasma concentration of Celecoxib is approximately 100% increased in elderly women (&gt;65 years).</p><p>Compared to subjects with normal hepatic function, patients with mild hepatic impairment had a mean increase in C of 53% and in AUC of 26% of Celecoxib. The corresponding values in patients with moderate hepatic impairment were 41% and 146% respectively. The metabolic capacity in patients with mild to moderate impairment was best correlated to their albumin values.</p><p>Treatment should be initiated at half the recommended dose in patients with moderate liver impairment (with serum albumin 25-35 g/l). Patients with severe hepatic impairment (serum albumin &lt;25 g/l) have not been studied and Celecoxib is contraindicated in this patient group.</p><p>There is little experience of Celecoxib in renal impairment. The pharmacokinetics of Celecoxib has not been studied in patients with renal impairment but is unlikely to be markedly changed in these patients. Thus caution is advised when treating patients with renal impairment. Severe renal impairment is contraindicated.</p><p><u>Elimination</u></p><p>Celecoxib is mainly eliminated by metabolism. Less than 1 % of the dose is excreted unchanged in urine. The inter-subject variability in the exposure of Celecoxib is about 10-fold. Celecoxib exhibits dose- and time-independent pharmacokinetics in the therapeutic dose range. Elimination half-life is 8-12 hours. Steady state plasma concentrations are reached within 5 days of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical safety data revealed no special hazard for humans based on conventional studies of repeated dose toxicity, mutagenicity or carcinogenicity beyond those addressed in section 4.4, 4.6, and 5.1 of the SmPC.</p><p>Celecoxib at oral doses &ge;150 mg/kg/day (approximately 2-fold human exposure at 200 mg twice daily as measured by AUC), caused an increased incidence of ventricular septal defects, a rare event, and fetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen when rabbits were treated throughout organogenesis. A dose-dependent increase in diaphragmatic hernias was observed when rats were given Celecoxib at oral doses &ge;30 mg/kg/day (approximately 6-fold human exposure based on the AUC at 200 mg twice daily) throughout organogenesis. These effects are expected following inhibition of prostaglandin synthesis. In rats, exposure to Celecoxib during early embryonic development resulted in pre-implantation and postimplantation losses, and reduced embryo/fetal survival.</p><p>Celecoxib was excreted in rat milk. In a peri-post natal study in rats, pup toxicity was observed.</p><p>In a 2 year toxicity study an increase in nonadrenal thrombosis was observed in male rat at high doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate.</p><p>Sodium Lauryl Sulphate.</p><p>Povidone K-30.</p><p>Croscarmellose Sodium.</p><p>Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Flamex® 200 Capsule → 3 Years (36 months).
Flamex® 400 Capsule → 2 Years (24 months).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary packaging: PVC/PVDC/ Aluminum blister.</p><p>Secondary packaging: Printed cardboard box containing the blisters&nbsp;and the package insert.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization
Joswe-medical
P.O. Box 851831 Amman 11185 Jordan 
E-mail: joswe@go.com.jo
www.joswe.com
Tel: +962 6 5859765, +962 6 5728327
Fax: +962 6 5814526, +962 6 5728326
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2023.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>